Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Currency in USD	2026
Operating Income	41.04 Million
Income Before Tax	46.19 Million
Income Tax Expense	11.38 Million
Net Income	34.81 Million
Eps	0.88
Epsdiluted	0.88
Weighted Average Shs Out	39.35 Million
Weighted Average Shs Out Dil	39.57 Million
Research And Development Expenses	N/A
Selling General And Administrative Expenses	198.51 Million
Depreciation And Amortization	5.62 Million
Interest Expense	311.00 Thousand
Interest Income	5.92 Million
Net Interest Income	5.60 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	264.94 Million
Ebitda	46.65 Million
Source	edgar
Ebit	46.50 Million

Penumbra, Inc. Annual Reports (10-K)